Eric Lefkofsky’s Post

We’re proud to announce our new partnership with The Company of Biologists. This collaboration integrates publications from their top journals into our AI-powered platform, ASCEND, giving scientists streamlined access to vital research including open and closed-access publications. Today, most scientists rely on the world’s scientific findings to advance scientific discovery. However, the increasing volume of research (over 1.5 million new articles annually) makes extracting up-to-date and reliable information a significant challenge. This often leads to unnecessary experimental errors and missed research opportunities. This partnership addresses this key challenge and empowers scientists with greater access to documented research, accelerating their work in drug discovery. Learn more about our partnership with The Company of Biologists and how we're empowering scientists across preclinical R&D:  https://lnkd.in/eiAg5JDz

Working with preclinical models of endocrine disrupting chemicals? I'm curating a collection of methods articles on JoVE, and I'd love your submission! This collection aims to consolidate various methodologies for delivering EDCs in vivo in animal models and assessing relevant endocrine-mediated endpoints, including, but not limited to, reproductive, metabolic, and neurobehavioral outcomes. Additionally, it focuses on the techniques used to elucidate the molecular, hormonal, and physiological mechanisms by which EDCs influence these endpoints, as well as the analytical methods essential for understanding the complex effects of EDCs on individuals. Creating a repository of this type of information for the field of EDC research will help foster a more standardized approach to the interdisciplinary study of EDCs, support the identification of new chemicals of concern, and provide consistent, evidence-based recommendations to regulatory bodies. Please check out the webpage at the link below, and consider submitting an abstract! https://lnkd.in/gMugNWQE

"An expert is a person who has made all the mistakes that can be made in a very narrow field." - Niels Bohr Symeres is dedicated to fostering collaboration and knowledge-sharing within the scientific community, and we're excited to support initiatives that promote continuous learning and development. That’s why we are thrilled to share that Symeres is proudly sponsoring an upcoming virtual event hosted by EFMC Young Scientists Network MedChemBio, focusing on the intriguing topic of 'Knowledge Creation from Failure'.   Date: March 26, 2024 Time: 16:30 to 18:30 HRS. CET   In today's dynamic landscape, embracing failure as a vital part of the learning process is paramount. This event promises to delve deep into the invaluable insights gained from setbacks, paving the way for innovation and growth within the realm of medicinal chemistry and biology.   We have a fantastic line-up of speakers and panelists e.g.: Gebhard Thoma of Novartis, Daniel Rauh of the TU Dortmund University, Stéphanie Guéret of AstraZeneca, and Tilly (Matilda) Bingham of Cumulus Oncology.    Save the date, mark your calendars, and register now via the link below to secure your spot at this enriching event! Let's unlock the power of failure together and propel our industry forward. Registration to the event is free and open to all. https://lnkd.in/dsXxDA5e   #EFMC #MedChemBio #VirtualEvent #Innovation #Science #Learning #Failure #Collaboration #Symeres #MakingMoleculesMatterTogether

New on Lab Insights: Wesley Wong, Consulting Team Manager at Roche Diagnostics APAC, interviews Professor Tony Badrick , CEO of The Royal College of Pathologists of Australasia (RCPA) and current Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB) president, where he outlines the environmental challenges faced by clinical labs today, why clinical labs should address it, and why it may not be as difficult as one might think. https://lnkd.in/gH9t7BcS

Although many people know about isotopes, few are aware of the word's origin. Originally coined in 1913 by the Scottish writer and pioneering female doctor Margaret Todd, it is derived from the Greek roots isos (ἴσος), meaning equal, and topos (τόπος), meaning "the same place." She proposed the term to British radiochemist Frederick Soddy to describe his concept of atoms of the same element with identical chemical properties but different atomic weights, in essence, occupying "the same place" in the periodic table of elements.   Stable isotope-labeled (SIL) compounds are those labeled with non-radioactive isotopes such as H-2, C-13, N-15 and O-18. They play important roles in the analysis of drug metabolites and agrochemicals, studies of reaction mechanisms and kinetics, and drug metabolism and pharmacokinetics (DMPK) research. Speak with one of GD3's experts to learn more about our deep experience in the synthesis of SIL-labeled compounds and how we can advance your drug discovery and development program. #medicinalchemistry  #DrugDiscovery   #GD3Services  https://lnkd.in/ezTBzjzk

Although many people know about isotopes, few are aware of the word's origin. Originally coined in 1913 by the Scottish writer and pioneering female doctor Margaret Todd, it is derived from the Greek roots isos (ἴσος), meaning equal, and topos (τόπος), meaning "the same place." She proposed the term to British radiochemist Frederick Soddy to describe his concept of atoms of the same element with identical chemical properties but different atomic weights, in essence, occupying "the same place" in the periodic table of elements.   Stable isotope-labeled (SIL) compounds are those labeled with non-radioactive isotopes such as H-2, C-13, N-15 and O-18. They play important roles in the analysis of drug metabolites and agrochemicals, studies of reaction mechanisms and kinetics, and drug metabolism and pharmacokinetics (DMPK) research. Speak with one of GD3's experts to learn more about our deep experience in the synthesis of SIL-labeled compounds and how we can advance your drug discovery and development program. #medicinalchemistry  #DrugDiscovery   #GD3Services  https://lnkd.in/ezTBzjzk

Although many people know about isotopes, few are aware of the word's origin. Originally coined in 1913 by the Scottish writer and pioneering female doctor Margaret Todd, it is derived from the Greek roots isos (ἴσος), meaning equal, and topos (τόπος), meaning "the same place." She proposed the term to British radiochemist Frederick Soddy to describe his concept of atoms of the same element with identical chemical properties but different atomic weights, in essence, occupying "the same place" in the periodic table of elements.   Stable isotope-labeled (SIL) compounds are those labeled with non-radioactive isotopes such as H-2, C-13, N-15 and O-18. They play important roles in the analysis of drug metabolites and agrochemicals, studies of reaction mechanisms and kinetics, and drug metabolism and pharmacokinetics (DMPK) research. Speak with one of GD3's experts to learn more about our deep experience in the synthesis of SIL-labeled compounds and how we can advance your drug discovery and development program. #medicinalchemistry  #DrugDiscovery   #GD3Services  https://lnkd.in/ezTBzjzk

Although many people know about isotopes, few are aware of the word's origin. Originally coined in 1913 by the Scottish writer and pioneering female doctor Margaret Todd, it is derived from the Greek roots isos (ἴσος), meaning equal, and topos (τόπος), meaning "the same place." She proposed the term to British radiochemist Frederick Soddy to describe his concept of atoms of the same element with identical chemical properties but different atomic weights, in essence, occupying "the same place" in the periodic table of elements.   Stable isotope-labeled (SIL) compounds are those labeled with non-radioactive isotopes such as H-2, C-13, N-15 and O-18. They play important roles in the analysis of drug metabolites and agrochemicals, studies of reaction mechanisms and kinetics, and drug metabolism and pharmacokinetics (DMPK) research. Speak with one of GD3's experts to learn more about our deep experience in the synthesis of SIL-labeled compounds and how we can advance your drug discovery and development program. #medicinalchemistry  #DrugDiscovery   #GD3Services  https://lnkd.in/ezTBzjzk

✨ Exciting News! ✨ The Life Sciences Research Company, a TBRC company, is advancing innovation in the life sciences sector. Stay tuned for groundbreaking updates and insights! #Marketresearchservices #Customresearchservices #Marketintelligence #Pharmaceuticalmarketresearch #Veterinaryhealthcareconsultingservices #Healthcareservicesmarketresearch #LifeSciences #Innovation #ResearchExcellence #TBRC

Our book entitled " Biosystems, Biomedical and Drug Delivery Systems: Characterization, Restoration and Optimization " is the new arrival published by Springer Nature.